XML 42 R34.htm IDEA: XBRL DOCUMENT v3.26.1
Discontinued Operations - Schedule of Details of Loss from Discontinued Operations (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenue [1] $ (29,285)  
Income tax (expense) benefit (39,200)  
Income (loss) from discontinued operations, net of tax 141,694 $ (2,663)
SomaScan Business    
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]    
Revenue [2] 37,172 20,573
Cost of revenue 4,504 11,880
Selling, general and administrative expenses 6,055 8,883
Research and development 2,881 5,888
Transaction and integration expenses 15,237 0
Total operating costs and expenses 28,677 26,651
Operating income (loss) 8,495 (6,078)
Other income, net 131 3,383
Gain on sale of business 172,289 0
Income (loss) from discontinued operations before income taxes 180,915 (2,695)
Income tax (expense) benefit (39,221) 32
Income (loss) from discontinued operations, net of tax $ 141,694 $ (2,663)
[1] Deferred revenue related to the Collaboration Agreement with Illumina was fully recognized upon the sale of the Disposed Entities. The Company has classified this revenue within discontinued operations consistent with the treatment of all SomaScan Business-related activities. Please see Note 2, Discontinued Operations, for more information.
[2] During the three months ended March 31, 2026, the Company recognized revenue of $29.8 million related to the transaction price under the Collaboration Agreement with Illumina, which primarily reflects the release of the deferred revenue balance previously established under the Collaboration Agreement upon the sale of the SomaScan Business. The Company has classified the $29.8 million within discontinued operations consistent with the treatment of all SomaScan Business-related activities. Out of the $29.8 million recognized, $0.6 million reflects Illumina’s exercise of its material right to be provided with SOMAmer reagents for commercialization of the co-branded kits.